Literature DB >> 19371501

Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse.

Naomi M Simon1.   

Abstract

Generalized anxiety disorder (GAD) has a high rate of comorbidity with other psychiatric disorders, including major depressive disorder (MDD), bipolar disorder, other anxiety disorders, and substance use disorders. The similarities between GAD and MDD have led some to suggest that GAD should be reclassified as a mood disorder. The concurrence of GAD with another disorder heightens a patient's risk for impairment, disability, and suicidality. Clinical trials for GAD and disorders that are most likely to occur with GAD have generally not taken comorbidity into account, and there is a paucity of data guiding how comorbidity should inform treatment selection. Research into the biology and psychopathology underlying the high rate of comorbidity of GAD and into efficacious interventions for GAD with comorbidity is needed. Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371501     DOI: 10.4088/jcp.s.7002.02

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

Review 1.  Searching human brain for mechanisms of psychiatric disorders. Implications for studies on schizophrenia.

Authors:  Sabina Berretta; Stephan Heckers; Francine M Benes
Journal:  Schizophr Res       Date:  2014-11-11       Impact factor: 4.939

Review 2.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

3.  Accuracy of a brief screening scale for lifetime major depression in cigarette smokers.

Authors:  Brian Hitsman; Stephen L Buka; Anna K Veluz-Wilkins; David C Mohr; Raymond Niaura; Stephen E Gilman
Journal:  Psychol Addict Behav       Date:  2011-09

4.  Intergenerational transmission of maternal overprotection and child anxiety in substance-using families.

Authors:  Qiong Wu; Jing Zhang; Natasha Slesnick
Journal:  J Anxiety Disord       Date:  2020-05-08

5.  Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.

Authors:  Evan Kyzar; Adam Michael Stewart; Samuel Landsman; Christopher Collins; Michael Gebhardt; Kyle Robinson; Allan V Kalueff
Journal:  Brain Res       Date:  2013-07-01       Impact factor: 3.252

Review 6.  Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress.

Authors:  Sayamwong E Hammack; Carolyn W Roman; Kimberly R Lezak; Margaret Kocho-Shellenberg; Bethany Grimmig; William A Falls; Karen Braas; Victor May
Journal:  J Mol Neurosci       Date:  2010-04-20       Impact factor: 3.444

7.  Intolerance of uncertainty: a common factor in the treatment of emotional disorders.

Authors:  James F Boswell; Johanna Thompson-Hollands; Todd J Farchione; David H Barlow
Journal:  J Clin Psychol       Date:  2013-02-04

Review 8.  Anxious depression: clinical features and treatment.

Authors:  Sanjai Rao; Sidney Zisook
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

Review 9.  Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches.

Authors:  Jeremy D Coplan; Cindy J Aaronson; Venkatesh Panthangi; Younsuk Kim
Journal:  World J Psychiatry       Date:  2015-12-22

Review 10.  Integrated treatment of substance use and psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley
Journal:  Soc Work Public Health       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.